DarioHealth Corp. found using ticker (DRIO) have now 5 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 35 and 10 with a mean TP of 21.45. Given that the stocks previous close was at 24.99 this now indicates there is a potential downside of -14.2%. The 50 day moving average now sits at 18.9 while the 200 day moving average is 15.32. The market cap for the company is $224m. You can visit the company’s website by visiting: http://mydario.com
DarioHealth Corp., a digital health company, develops and commercializes patented and proprietary technologies providing consumers with laboratory-testing capabilities using smart phones and other mobile devices in the United States, Europe, Australia, and Canada. The company’s flagship product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with Dario Blood Glucose Monitoring System, a pocket-sized, blood glucose monitoring device. It offers DarioEngage software platform, where the company digitally engages with Dario users and assists them in monitoring their chronic illnesses, as well as provides them with coaching, support, digital communications; and real time alerts, trends, and pattern analysis. DarioHealth Corp. markets its products directly to consumer cash sales, as well as retail pharmacy, hospitals, and distributors; and through online. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was founded in 2011 and is headquartered in Caesarea, Israel.